BNP Paribas Asset Management’s BioCryst Pharmaceuticals BCRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $15K | Buy |
+1,664
| New | +$15K | ﹤0.01% | 1611 |
|
|
2023
Q4 | – | Sell |
-2,390,948
| Closed | -$16.9M | – | 849 |
|
|
2023
Q3 | $16.9M | Sell |
2,390,948
-19,242
| -0.8% | -$136K | 0.05% | 315 |
|
|
2023
Q2 | $17M | Sell |
2,410,190
-477,549
| -17% | -$3.36M | 0.05% | 306 |
|
|
2023
Q1 | $24.1M | Buy |
2,887,739
+25,352
| +0.9% | +$211K | 0.08% | 255 |
|
|
2022
Q4 | $32.9M | Buy |
2,862,387
+581,434
| +25% | +$6.67M | 0.12% | 207 |
|
|
2022
Q3 | $28.7M | Buy |
2,280,953
+181,626
| +9% | +$2.29M | 0.11% | 213 |
|
|
2022
Q2 | $22.2M | Buy |
2,099,327
+434,071
| +26% | +$4.59M | 0.08% | 262 |
|
|
2022
Q1 | $27.1M | Sell |
1,665,256
-225,904
| -12% | -$3.67M | 0.09% | 252 |
|
|
2021
Q4 | $26.2M | Buy |
+1,891,160
| New | +$26.2M | 0.09% | 267 |
|
|
2015
Q1 | – | Sell |
-16,328
| Closed | -$199K | – | 1051 |
|
|
2014
Q4 | $199K | Buy |
+16,328
| New | +$199K | ﹤0.01% | 949 |
|